JenaValve’s Trilogy System Sees Initial Clinical Use at Scripps Health

According to a recent LinkedIn post from JenaValve Technology Inc, the Trilogy System has been used in four initial cases at Scripps Health in San Diego under the leadership of Dr. Curtis Stinis and the local heart team. The post characterizes this as part of growing momentum for what it describes as the first and only FDA-approved transcatheter aortic valve replacement, or TAVR, device for aortic regurgitation in the U.S.

The LinkedIn content emphasizes that the Trilogy System targets patients with symptomatic, severe aortic regurgitation who are considered high risk for surgery and underscores JenaValve’s collaboration with what it calls pioneering clinical teams. The message also indicates an intention to expand access to the therapy nationwide, while including standard U.S. regulatory cautions and directing readers to full safety information on the company’s website.

For investors, the reported clinical adoption at a recognized institution like Scripps Health may signal early commercial traction in a niche but underserved structural heart indication. If similar launches occur across additional centers, this could support revenue growth, validate reimbursement pathways, and reinforce JenaValve’s competitive positioning in TAVR solutions specifically designed for aortic regurgitation.

The focus on high-risk surgical patients suggests a clear initial target market where transcatheter options may command premium pricing and strong clinical demand. However, future financial impact will depend on broader hospital uptake, long-term clinical outcomes, regulatory and safety considerations, and how competing technologies evolve in the U.S. structural heart market.